Drugs Context. 2026 Jul 1;15:2026-5-3. doi: 10.7573/dic.2026-5-3. eCollection 2026.
ABSTRACT
BACKGROUND: Bimekizumab, a dual IL-17A and IL-17F inhibitor, has demonstrated high efficacy in moderate- to-severe psoriasis in clinical trials. However, real-world evidence in patients with moderate disease remains limited.
METHODS: This retrospective multicentre study evaluated the effectiveness and safety of bimekizumab over 54 weeks in adults with moderate plaque psoriasis treated across five dermatology centres in the Lazio region (Italy).
RESULTS: Fifty-nine patients initiated treatment, and 50 completed follow-up; PASI data at week 54 were available for 19 patients, whilst nail data at week 54 were available for 23 patients. Mean Psoriasis Area and Severity Index (PASI) decreased from 9.20 at baseline to 1.31 at week 4, 0.31 at week 16, 0.09 at week 24 and 0.05 at week 54. Nail involvement improved progressively, with mean Nail Psoriasis Severity Index declining from 2.96 at baseline to 0.03 at week 24, with complete clearance observed in all evaluable patients at week 54. More than 60% of patients achieved PASI90 by week 4, almost 90% reached PASI90 and approximately 88% achieved PASI100 by week 16, whilst nearly all patients attained complete clearance (PASI100) by week 54. Responses were comparable between biologic-naive and biologic-experienced patients. Adverse events occurred in 8 patients (13.6%), predominantly mild oral candidiasis, with no serious adverse events or treatment discontinuations.
CONCLUSION: These findings suggest that bimekizumab provides rapid and sustained skin clearance with favourable tolerability in patients with moderate psoriasis, supporting the consideration of early systemic treatment as a potential strategy to reduce disease burden in this population.
PMID:42422714 | PMC:PMC13344332 | DOI:10.7573/dic.2026-5-3